• 486 patients with insufficiently treated hypertension were observed for 24 weeks in a double-blind, double-dummy study with olmesartan (OLM)/amlodipine (AML) or perindopril (PER)/AML in 16 hypertension/nephrology centres in Spain.

• The primary objective was to show non-inferiority of the fixed-dose combination of OLM/AML 40/10 mg compared to PER/AML 8/10 mg in central arterial BP from baseline to final examination.

• Secondary objectives included absolute changes in systolic and diastolic conventional blood pressure (BP) measurements, ambulatory BP monitoring, number of BP normalisers and responders and incidence of AEs.

• For the primary objective, the non-inferiority margin of 2 mmHg was fulfilled by an upper CI limit of -1.83 mmHg.

• The test of superiority integrated in the ANCOVA model was in favour of the combination of OLM/AML compared with PER/AML. The results for the secondary efficacy variables were consistent with those of the primary efficacy endpoint.

This summary slide represents the opinions of the authors, and not necessarily the opinions of the publisher or editorial board. This material has been peer reviewed. Sponsorship for this study and summary slide was funded by Daiichi Sankyo Europe GmbH. Medical writing assistance for this study and summary slide was provided by Phil Jones, PhD, of inScience Communications. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online.